Therapeutic Insights

Found 994 articles

• Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s

  4/18/2023

  Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).

• Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

  4/18/2023

  Alzheon, Inc. announced that it will be presenting baseline imaging characteristics from ongoing APOLLOE4 Phase 3 clinical trial and 12-month results from the Phase 2 biomarker study evaluating ALZ-801 oral tablet at the upcoming American Academy of Neurology Conference to be held from April 22 – April 27, 2023 in Boston, Massachusetts.

• 

  Top 2023 Neurodegenerative Readouts

  4/17/2023

  Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets.

• ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease

  4/13/2023

  ZyVersa Therapeutics, Inc. announces publication of a review article in Frontiers in Pharmacology addressing the NLRP3 inflammasome pathway as a potential drug target for treating mild cognitive impairment (“MCI”) and AD.

• Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

  4/13/2023

  Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease.

• ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS

  4/13/2023

  Annovis Bio, Inc. today announced that the Company will hold a live R&D webcast to review its clinical development programs in Alzheimer's disease and Parkinson's disease.

• Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda

  4/11/2023

  Treventis Corporation, a privately held biotechnology company, announced today that it has entered an option, collaboration, and license agreement with Takeda for the further research, development, and commercialization of small molecules that target tau, a key protein in Alzheimer's Disease (AD).

• ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

  4/10/2023

  ProMIS Neurosciences Inc. today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of AD.

• Newly Published Study Demonstrates the Clinical Effectiveness of Machine Learning Used to Achieve Remission in Patients with Peanut Allergies

  4/5/2023

  The Food Allergy Institute announced that a peer reviewed paper authored by its founder Inderpal Randhawa, MD, has been published by the clinical journal PLOS ONE.

• 

  Lilly Debuts Next Alzheimer’s Drug, Will Test Subcutaneous Potential

  4/4/2023

  With data from the Phase III trial of donanemab expected in Q2, Eli Lilly presented the first clinical results from its next anti-amyloid antibody, remternetug, at AD/PD 2023.

• EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023

  4/3/2023

  EIP Pharma Inc. announced the oral presentation by academic investigators from the Amsterdam University Medical Center of neuroimaging results from a phase 2a clinical study in patients with early Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases 2023, which took place virtually and in person March 28 – April 1, 2023, in Gothenburg, Sweden.

• BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference

  4/3/2023

  BioArctic AB and its partner Eisai has presented new findings on lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's disease, at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders.

• Eisai publishes additional detailed analyses from lecanemab phase 2b study

  3/31/2023

  BioArctic AB's partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer's disease and mild AD.

• 

  Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study

  3/30/2023

  BIIB080 successfully reduced tau pathology in patients with early-stage disease across all six brain regions analyzed.

• AlzeCure Presents New Data at Alzheimer’s Conference AD/PD on the Potential Disease-Modifying Effect of NeuroRestore ACD856

  3/30/2023

  AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website.

• Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

  3/29/2023

  Gain Therapeutics, Inc. today announced the presentation of new pre-clinical data supporting the potential of its structurally targeted allosteric regulators (STARs) of glucocerebrosidase (GCase) to prevent neurodegeneration in Alzheimer’s disease (AD).

• AlzeCure Presents New Data on its Preventive Treatment Alzstatin at the Alzheimer's Conference AD/PD 2023

  3/28/2023

  AlzeCure Pharma AB announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website.

• EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer's and Parkinson's diseases in Multiple Disease Models

  3/28/2023

  EpicentRx, Inc. has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer's & Parkinson's Diseases  taking place in Gothenburg, Sweden  during  March 28-April 1, 2023.  

• Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

  3/27/2023

  Acumen Pharmaceuticals, Inc.  today reported financial results for the full year ended December 31, 2022 and provided a business update.

• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/24/2023

  ASLAN Pharmaceuticals today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.